rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    JAGX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Jaguar Health to Hold Investor Webcast November 17 Regarding Q3 2026 Financials & Corporate Updates
      Nov 13Yahoo FinanceJAGX
      Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
      Nov 6Yahoo FinanceJAGX
      Jaguar Health completes conversion of Series R preferred stock to common shares
      Nov 3Investing.comJAGX
      CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
      Nov 2Yahoo FinanceJAGX
      Jaguar Health board approves six-fold increase to stock incentive plan share reserve
      Oct 28Investing.comJAGX
      Jaguar Health unit treats infant with rare intestinal disorder
      Oct 21Investing.comJAGX
      Jaguar Health sets ex-dividend date for special stock dividend
      Oct 15Investing.comJAGX
      Jaguar Health Provides Update Regarding Special Stock Dividend
      Oct 14Yahoo FinanceJAGX
      Jaguar Health unit reports crofelemer study results in bowel syndrome
      Oct 14Investing.comJAGX
      Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
      Oct 14Yahoo FinanceJAGX
      Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
      Oct 13Yahoo FinanceJAGX
      Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances

      Jaguar Health subsidiary Napo Pharmaceuticals is continuing its global crofelemer development program for rare intestinal failure diseases while preparing for a planned mid-2027 New Drug Application filing for microvillus inclusion disease. Key Investor TakeawaysJaguar Health (NASDAQ:JAGX) continues to target a mid-2027 MVID NDA filing for crofelemer powder for oral solution.

      Oct 6Yahoo FinanceJAGX
      Jaguar Health Declares Special Series R Preferred Dividend

      Detailed price information for Jaguar Health Inc (JAGX-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailJAGX
      Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
      Oct 6Yahoo FinanceJAGX
      12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Jaguar Health (NASDAQ:JAGX), Option Care H

      Gainers Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-market session. The company's market cap stands at $2.4 million. Option Care Health (NASDAQ:OPCH) stock rose

      Oct 6BenzingaJAGXOPCH
      Why Option Care Health Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket
      Oct 6BenzingaFRGTJAGXOPCH
      Jaguar Health Stock Soars 35% After Hours - Jaguar Health (NASDAQ:JAGX)

      Jaguar Health shares surged 34.67% after hours Monday following the company’s special dividend announcement and debt-payment extensions.

      Oct 6BenzingaJAGX
      Jaguar Health Announces a Special Stock Dividend
      Oct 3Yahoo FinanceJAGX
      Napo Pharmaceuticals Crofelemer Study Accepted for Presentation at ACG 2026

      Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), said an abstract covering preliminary results from an ongoing study of crofelemer in adults with short bowel syndrome with intestinal failure has been accepted for presentation at the American College of Gastroenterology Annual Scientific Meeting. ACG 2026 is scheduled to take place from October 9 to October 14 in Nashville, Tennessee.

      Sep 29Yahoo FinanceJAGX
      Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
      Sep 29Yahoo FinanceJAGX
      Jaguar Animal Health Executes Major Debt-for-Equity Exchange

      Detailed price information for Jaguar Health Inc (JAGX-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailJAGX
      Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float

      Jaguar Health is surging on a float so thin that a handful of trades can swing the price wildly, while a rare pediatric disease program edges closer to a pivotal regulatory filing that could either validate the rally or expose how fragile it really is.

      Sep 25Yahoo FinanceJAGX
      Jaguar Health Stock Surges Friday: What's Happening? - Jaguar Health (NASDAQ:JAGX)

      Jaguar Health is surging Friday after announcing debt-for-equity exchanges that cut debt by over $6.7 million and retired a promissory note.

      Sep 25BenzingaJAGX
      Jaguar Health Stock Slides Thursday: What's Happening? - Jaguar Health (NASDAQ:JAGX)

      Jaguar Health shares are sliding Thursday as equity dilution concerns weigh on the company following a debt-for-equity exchange.

      Sep 24BenzingaJAGX
      Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%

      Two biotech stocks are getting crushed while the sector benchmark climbs, and the reasons behind each selloff could not be more different. Understanding what separates a deliberate corporate move from pure micro-cap chaos is the key to reading both situations correctly.

      Sep 24Yahoo FinanceJAGXVKTX
      12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

      Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares

      Sep 23BenzingaADGMARTLJAGXVTGN
      Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%
      Sep 23Yahoo FinanceJAGXVKTX
      Jaguar Health Stock Plunges Wednesday: What's Happening? - Jaguar Health (NASDAQ:JAGX)

      Jaguar Health shares are plunging Wednesday morning as profit-taking reverses an explosive Tuesday rally sparked by regulatory fee waivers.

      Sep 23BenzingaJAGX
      12 Health Care Stocks Moving In Wednesday's Pre-Market Session - IM Cannabis (NASDAQ:IMCC), Vistagen Ther

      Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares increased by

      Sep 23BenzingaIMCCJAGX
      InnovAge, Voyager Technologies And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Inno

      U.S. futures edged higher; InnovAge fell 9.4% after a 10M-share offering. Jaguar Health, Voyager Technologies and other stocks also dropped premarket.

      Sep 23BenzingaINNVJAGX
      Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

      Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.

      Sep 23BenzingaJAGXWOR
      JAGX Stock Soars Over 10% Premarket After Best Day In Over 8 Years: What’s Driving The Surge?

      Jaguar Health aims to file for approval of its Crofelemer powder treatment for pediatric MVID in mid-2027.

      Sep 23Yahoo FinanceJAGX
      Endovia Health Sciences Stock Jumps 48% After Hours - Endovia Health Sciences (AMEX:EDVA)

      Endovia Health Sciences shares jumped 47.83% after hours Tuesday as investors cheered fresh funding for its CannEpil drug program.

      Sep 23BenzingaJAGX
      Jaguar Health Shares Jump 5.19% After Hours - Jaguar Health (NASDAQ:JAGX)

      Jaguar Health shares jumped 5.19% after hours following FDA fee waivers for two of its commercialized therapies.

      Sep 23BenzingaJAGX
      Jaguar Health, IONQ, Viking Therapeutics, Xanadu Quantum and Grab Holdings: Why These 5 Stocks Are on Inv

      JAGX, IONQ, VKTX, XNDU, GRAB were among the stocks seen trending on Tuesday, Sept. 22, 2026.

      Sep 23BenzingaGRABWJAGXVKTXIONQ
      12 Health Care Stocks Moving In Tuesday's After-Market Session - Jaguar Health (NASDAQ:JAGX), Bullfrog AI

      Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares

      Sep 22BenzingaBFRGJAGXJUNS
      12 Health Care Stocks Moving In Tuesday's Intraday Session - Jaguar Health (NASDAQ:JAGX), Greenland Mines

      Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved upwards by

      Sep 22BenzingaCMPXJAGX
      FDA grants fee waivers to Jaguar Health for two drugs
      Sep 22Investing.comJAGX
      Jaguar Health Receives Fee Waivers from FDA

      Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Pres

      Sep 22Yahoo FinanceJAGX
      Jaguar Health to implement 1-for-15 reverse stock split
      Sep 15Investing.comJAGX
      Jaguar Health, Inc. Announces Reverse Stock Split

      The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX". The new CUSIP number for the Company's Common Stock following the reverse stock split is 47010C854.

      Sep 15Yahoo FinanceJAGX
      Jaguar Health’s Napo unit advances MVID trial toward 2027 filing
      Sep 10Investing.comJAGX
      Jaguar Health Stock Slides Thursday: What's Happening?
      Sep 10BenzingaJAGX
      All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

      The trial is ongoing at multiple centers in the United States, the European Union, and the United Arab Emirates. This trial is expected to support a New Drug Application (NDA) filing for the treatment of the MVID indication in mid-2027.

      Sep 10Yahoo FinanceJAGX
      Jaguar Health Launches Neonorm Dog on Amazon, Expanding Animal-Health Product Franchise

      The non-prescription digestive-support product extends Jaguar Health’s Neonorm franchise into the companion-animal market, with additional online and retail distribution expected shortly. Key Investor TakeawaysJaguar Health (NASDAQ:JAGX) has launched Neonorm Dog on Amazon as part of the commercial rollout of its new non-prescription animal-health product.

      Sep 8Yahoo FinanceJAGX
      Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
      Sep 8MorningstarJAGX
      Jaguar Health plans MVID drug application for mid-2027
      Sep 4Investing.comJAGX
      Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

      Napo remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric rare IF diseases, including microvillus inclusion disease (MVID) and short bowel syndrome with IF (SBS-IF). In June 2026, as announced, data was presented at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting in Lille, France from ongoing investigational studies with oral liquid crofelemer

      Sep 4Yahoo FinanceJAGX
      12 Health Care Stocks Moving In Tuesday's After-Market Session
      Sep 1BenzingaINBSJAGX
      Jaguar Health launches Neonorm Dog for digestive support
      Aug 26Investing.comJAGX

      This is the newest page. Registered accounts read further back.